Qiagen LLC DNA Isolation Kits
ID: 25-000010Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/d94a99dd361a4adfb19207fd0ea73d5c/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure DNA Isolation Kits from Qiagen LLC on a sole source basis. The acquisition aims to supply the Human Leukocyte Antigen (HLA) Lab with essential testing kits that have been rigorously tested to ensure high-quality DNA samples for critical patient testing. These kits are vital for HLA typing, particularly for critically ill patients, as they directly impact the turnaround time for results necessary for lifesaving transplants. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by October 31, 2024, at 6:30 AM EST, as this is not a request for proposals.

    Point(s) of Contact
    Shasheshe Goolsby
    (301) 827-4879
    shasheshe.goolsby@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Qiagen LLC DNA Isolation Kits
    Currently viewing
    Presolicitation
    Similar Opportunities
    CareDX Lab Solutions Inc. Allo Seq Tx17 Next Generation Sequencing (NGS) Reagent Kits
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to issue a sole source firm fixed-price purchase order to CareDx Lab Solutions Inc. for the procurement of Allo Seq Tx17 Next Generation Sequencing (NGS) reagent kits. This acquisition aims to secure a one-year supply of NGS reagents necessary for the Human Leukocyte Antigen (HLA) Laboratory within the Department of Transfusion Medicine, ensuring adequate stock for patient testing through quarterly shipments scheduled from November 2024 to August 2025. The HLA Laboratory plays a critical role in providing diagnostic testing and consultations for transplant eligibility, maintaining accreditation, and engaging in research for new diagnostic tests. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by October 30, 2024, at 6:30 AM EST, as this is not a request for proposals.
    Title: Global Life Sciences Sepax Cell Separation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed-price contract for the procurement of Global Life Sciences Sepax Cell Separation Kits and Ficoll Paque Premium reagents. The NIH's Department of Transfusion Medicine requires these items to support the manufacturing of cell-based therapies for patients with advanced metastatic cancer, utilizing the Sepax C-Pro Cell Processing Instruments. This acquisition is being conducted under the Simplified Acquisition Procedures, allowing for a sole-source award to Cytiva-Global Life Sciences Solutions USA LLC, with capability statements due by November 3, 2024, at 12:00 PM EST. Interested parties can direct inquiries to Sheri Eiri at sheri.eiri@nih.gov.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of cDNA-PCR sequencing kits for long-read sequencing, as part of a Sources Sought notice. The primary objective is to procure PromethION flow cells and sequencing kits that are compatible with the Oxford Nanopore PromethION device, which is essential for high-throughput sequencing in research on Alzheimer’s disease and related dementias. These consumables will facilitate the analysis of DNA and RNA samples, aiding in the identification of potential therapeutic targets and biomarkers for Alzheimer's disease. Interested companies must submit their capability statements by October 28, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov, ensuring that all submissions adhere to the specified guidelines and page limits.
    Sources Sought-BioFire Reagents and Test Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is conducting a Sources Sought announcement to identify potential qualified small businesses capable of supplying BioFire Defense reagents and test kits. The NIH's Department of Laboratory Medicine requires these reagents for their BioFire FilmArray analyzers, which are essential for the rapid detection of infectious agents from clinical samples, thereby facilitating timely treatment. Interested vendors must submit their company information, including a capability statement, by 12:00 PM EST on November 7, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the government will not reimburse any costs associated with this request.
    Notice of Intent to Sole Source - Biosearch Technologies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) intends to negotiate a sole source contract with Biosearch Technologies, Inc. for the production of proprietary PCR kits essential for the Laboratory Response Network (LRN). The procurement aims to ensure a consistent supply of reagents necessary for detecting biothreat agents and emerging infectious diseases, which are critical for national preparedness and response capabilities. These kits, which must comply with FDA quality standards, are vital for high-security laboratories and are designed to identify various bioterrorism agents. Interested parties may submit capability statements or proposals to Matthew Nelson at mnelson2@cdc.gov by November 7, 2024, at 3:30 PM EST for consideration.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of assay kits for the Lumipulse G1200 instrument, which is essential for conducting assays related to Alzheimer's disease biomarkers. The procurement aims to acquire state-of-the-art assay kits for quantifying serum/plasma levels of abeta42, abeta40, and pTau 217, which will be utilized in ongoing research involving stored specimens from the Baltimore Longitudinal Study of Aging (BLSA). Interested vendors are encouraged to submit capability statements detailing their ability to meet the project requirements, including manufacturing details and company qualifications, by October 28, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov. This notice serves as a Sources Sought announcement and does not constitute a solicitation for proposals or quotes.
    Maintenance Service for two (2) Illumina NextSeq™ 1000 Sequencers
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Illumina, Inc. for maintenance services on two Illumina NextSeq™ 1000 Sequencers. The contract will cover comprehensive support, including parts, labor, travel, and technical assistance, essential for high-throughput next-generation sequencing used in diagnosing inherited immune disorders. This acquisition is critical as Illumina is the sole manufacturer with the necessary components and expertise to maintain the equipment to its original specifications. Interested parties capable of providing similar services may submit a capability statement to Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov, with submissions due by the specified deadline.
    Notice of Intent to Sole Source; Monument Medical
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Monument Medical Inc. for the procurement of amicus apheresis kits, which are essential for mononuclear cell collection at the NIH Clinical Center blood bank. This acquisition is critical due to the urgency of the requirement, as a delay could impact the availability of blood bags necessary for immediate patient care. The contract will be awarded under simplified acquisition procedures, with a total quantity of 240 kits required, and interested parties may submit their capabilities and interest to the NIH by November 1, 2024, at 10 AM EST, via email to Kristin Nagashima at kristin.nagashima@nih.gov.
    Gibco EXPI293 Expression Media 6 x 1L, catalog # A1435102 and 2) EXPIFECTAMINE TRANSFXN KIT 10L 10L Kit Catalog# A14525
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for the procurement of specific commercial items, namely the EXPI293 Expression Medium and the Expifectamine Transfection Kit, under solicitation number RFQ-NIAID-25-2244965. The procurement involves a total of 36 units of the expression medium to be delivered in six scheduled shipments from January to November 2025, along with one delivery of ten transfection kits, all adhering to strict quality and expiration date criteria. These products are critical for biological research and development, particularly in the fields of allergy and infectious diseases. Interested vendors must submit their proposals by October 30, 2023, via the NIH's electronic Simplified Acquisition Submission System (eSASS), and are required to be registered in the System for Award Management (SAM) prior to submission. For further inquiries, contact Calvin Robinson at calvin.robinson@nih.gov or by phone at 406-363-9214.